CRPC

Safety of the Novel Actinium-225-PSMA Radioligand Therapy for mCRPC
Research conducted by Mike Sathekge, MD, and colleagues sought to determine the safety and potential antitumor activity of the novel actinium-225 (225Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) in treating patients with metastatic castration-resistant prostate cancer (mCRPC). The study was published in The Lancet Oncology. ...
Advertisement

Latest News

Advertisement

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer
Prostate Cancer

Conference Coverage

Advertisement
Advertisement
Trending